As an example, CAR T cells with low affinity scFvs targeting HER2 and CD19 have demonstrated sustained functionality and reduced exhaustion in preclinical murin models and in leukemia patients, respectively [29, 30]. This evidence concerns the gene CD19 and leukemia.